Eiger BioPharmaceuticals, Inc.
DelistedCIK 1305253fmd_1XY2AQ33GVNSMZ7DNZZ6BJMBBTManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2012 to Dec 31, 2023, 45 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 0 | 12 | 13 | 16 |
| Cost of revenue | – | – | – | – | – | – | 0 | 1 | 2 | 0 |
| Gross profit | – | – | – | – | – | – | 0 | 11 | 12 | 16 |
| Research and development | 1 | 8 | 33 | 30 | 37 | 52 | 42 | 64 | 75 | 62 |
| Selling, general and administrative | – | – | – | – | – | 17 | 21 | 24 | 29 | 25 |
| Total operating expenses | 2 | 13 | 46 | 42 | 51 | 69 | 62 | – | – | – |
| Operating income | (2) | (13) | (46) | (42) | (51) | (69) | (62) | (77) | (93) | (72) |
| Interest expense | 1 | 0 | 1 | 2 | 2 | 3 | 4 | 4 | 4 | 5 |
| Interest and investment income | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 1 | 2 |
| Other non-operating income (expense) | (0) | 0 | (0) | 0 | (0) | (0) | (0) | 46 | (1) | 0 |
| Income before taxes | – | – | – | – | – | (70) | (65) | (34) | (97) | (75) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (70) | (65) | (34) | (97) | (75) |
| Net income | (2) | (13) | (47) | (42) | (52) | (70) | (65) | (34) | (97) | (75) |
| Net income to common shareholders | (34) | (44) | – | – | – | – | – | – | – | – |